Premium
Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices
Author(s) -
Cuker Adam
Publication year - 2018
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25092
Subject(s) - medicine , rituximab , second line therapy , intensive care medicine , immune thrombocytopenia , quality of life (healthcare) , first line , disease , first line therapy , medline , immunology , chemotherapy , antibody , nursing , political science , law
In patients with immune thrombocytopenia who do not adequately respond to first‐line therapy, there is no clear consensus on which second‐line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long‐term use (eg, corticosteroids) and overuse of off‐label therapies (eg, rituximab) while approved, more efficacious options exist. These approaches may not only fail to address symptoms and burden of disease, but may also worsen health‐related quality of life. A better understanding of available second‐line treatments may ensure best use of therapeutic options and thereby optimize patient outcomes.